MAP2K7 and synovial sarcoma: Prospective clinical trials are needed to evaluate the efficacy and safety of BRAF<sup>V600E</sup> & MEK inhibitors as a therapeutic approach in BRAF<sup>V600E</sup> synovial sarcoma.